{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:04:12Z","timestamp":1790305452577,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"publisher","award":["EGFRIFOSCC-E65F22000050001"],"award-info":[{"award-number":["EGFRIFOSCC-E65F22000050001"]}],"id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tvjl.2026.106648","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T15:51:52Z","timestamp":1773589912000},"page":"106648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Expression of VEGF-A\/VEGFR-2 pathway in feline oral squamous cell carcinoma in vitro and anti-tumour effect of Bevacizumab in a xenograft model"],"prefix":"10.1016","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-0821","authenticated-orcid":false,"given":"Gennaro","family":"Altamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-0574","authenticated-orcid":false,"given":"Domenico","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Squillacioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8264-5755","authenticated-orcid":false,"given":"Carmen","family":"Avagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pelagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Borzacchiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2026.106648_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1593\/neo.11948","article-title":"The effect of bevacizumab on human malignant melanoma cells with functional VEGF\/VEGFR2 autocrine and intracrine signaling loops","volume":"14","author":"Adamcic","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.tvjl.2026.106648_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.oraloncology.2018.11.027","article-title":"HPV related head and neck squamous cell carcinoma: new evidences for an emerging spontaneous animal model","volume":"88","author":"Altamura","year":"2019","journal-title":"Oral Oncology"},{"key":"10.1016\/j.tvjl.2026.106648_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.1040552","article-title":"Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines","volume":"9","author":"Altamura","year":"2022","journal-title":"Frontiers in veterinary Science"},{"key":"10.1016\/j.tvjl.2026.106648_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2023.1148673","article-title":"Feline oral squamous cell carcinoma and Felis catus papillomavirus: is it time to walk the path of human oncology?","volume":"10","author":"Altamura","year":"2023","journal-title":"Frontiers in veterinary Science"},{"key":"10.1016\/j.tvjl.2026.106648_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/vco.12943","article-title":"Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial-mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro","volume":"22","author":"Altamura","year":"2024","journal-title":"Veterinary and Comparative Oncology"},{"key":"10.1016\/j.tvjl.2026.106648_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35723-7","article-title":"Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP\/p53 binding and enhances p53 proteasomal degradation","volume":"8","author":"Altamura","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.tvjl.2026.106648_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.tvjl.2026.106648_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/vetsci9070375","article-title":"Characterization of the Expression of Angiogenic Factors in Cutaneous Squamous Cell Carcinoma of Domestic Cats","volume":"9","author":"Gudenschwager-Basso","year":"2022","journal-title":"Veterinary Sciences"},{"key":"10.1016\/j.tvjl.2026.106648_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance Mechanisms to Anti-angiogenic Therapies in Cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.tvjl.2026.106648_bib10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1177\/0300985819859873","article-title":"Immunohistochemical Features of Epithelial-Mesenchymal Transition in Feline Oral Squamous Cell Carcinoma","volume":"56","author":"Harris","year":"2019","journal-title":"Veterinary Pathology"},{"key":"10.1016\/j.tvjl.2026.106648_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1556\/004.2020.00005","article-title":"Expression levels of angiogenic growth factors in feline squamous cell carcinoma","volume":"68","author":"Kabak","year":"2020","journal-title":"Acta Veterinaria Hungarica"},{"key":"10.1016\/j.tvjl.2026.106648_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1292\/jvms.64.453","article-title":"Nucleotide sequence and expression of the feline vascular endothelial growth factor","volume":"64","author":"Koga","year":"2002","journal-title":"The Journal of veterinary Medical Science"},{"key":"10.1016\/j.tvjl.2026.106648_bib13","article-title":"Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab","volume":"12","author":"Liu","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.tvjl.2026.106648_bib14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12917-018-1576-z","article-title":"Expression of vascular endothelial growth factor (VEGF) in equine sarcoid","volume":"14","author":"Martano","year":"2018","journal-title":"BMC veterinary Research"},{"key":"10.1016\/j.tvjl.2026.106648_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3892\/ol.2015.3847","article-title":"Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas","volume":"11","author":"Martano","year":"2016","journal-title":"Oncology Letters"},{"key":"10.1016\/j.tvjl.2026.106648_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.oraloncology.2011.12.012","article-title":"Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma","volume":"48","author":"Martin","year":"2012","journal-title":"Oral Oncology"},{"key":"10.1016\/j.tvjl.2026.106648_bib17","doi-asserted-by":"crossref","first-page":"8607","DOI":"10.1158\/0008-5472.CAN-10-0850","article-title":"Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma","volume":"70","author":"Martin","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/j.tvjl.2026.106648_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41199-020-00051-9","article-title":"An update on angiogenesis targeting in head and neck squamous cell carcinoma","volume":"5","author":"Micaily","year":"2020","journal-title":"Cancers of the Head & Neck"},{"key":"10.1016\/j.tvjl.2026.106648_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1292\/jvms.15-0550","article-title":"Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma","volume":"78","author":"Michishita","year":"2016","journal-title":"The Journal of veterinary Medical Science"},{"key":"10.1016\/j.tvjl.2026.106648_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1254\/jphs.12268SC","article-title":"Antitumor effect of bevacizumab in a xenograft model of canine hemangiopericytoma","volume":"121","author":"Michishita","year":"2013","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.tvjl.2026.106648_bib21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.rvsc.2006.01.007","article-title":"The role of vascular endothelial growth factor and its receptor Flk-1\/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops","volume":"81","author":"Millanta","year":"2006","journal-title":"Research in veterinary Science"},{"key":"10.1016\/j.tvjl.2026.106648_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.rvsc.2019.03.018","article-title":"In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor","volume":"124","author":"Muellerleile","year":"2019","journal-title":"Research in Veterinary Science"},{"key":"10.1016\/j.tvjl.2026.106648_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010117","article-title":"Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma","volume":"13","author":"Nascimento","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tvjl.2026.106648_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/10406387251315677","article-title":"vitro expression of genes encoding HIF1alpha, VEGFA, PGE2 synthases, and PGE2 receptors in feline oral squamous cell carcinoma","volume":"37","author":"Nasry","year":"2025","journal-title":"Journal of Veterinary diagnostic investigation Official Publication of the American Association of Veterinary Laboratory Diagnosticians Inc"},{"key":"10.1016\/j.tvjl.2026.106648_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041264","article-title":"Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2","volume":"19","author":"Peach","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.tvjl.2026.106648_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.critrevonc.2013.05.009","article-title":"Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review","volume":"88","author":"Ranieri","year":"2013","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.tvjl.2026.106648_bib27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41416-020-0892-9","article-title":"Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC","volume":"123","author":"Rong","year":"2020","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.tvjl.2026.106648_bib28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2460\/ajvr.74.5.771","article-title":"Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice","volume":"74","author":"Scharf","year":"2013","journal-title":"American Journal of veterinary Research"},{"key":"10.1016\/j.tvjl.2026.106648_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/cnr2.1802","article-title":"Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review","volume":"6","author":"Tamimi","year":"2023","journal-title":"Cancer Reports"},{"key":"10.1016\/j.tvjl.2026.106648_bib30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1290\/1071-2690(2001)037<0676:FHANSC>2.0.CO;2","article-title":"Feline head and neck squamous cell carcinoma cell line: characterization, production of parathyroid hormone-related protein, and regulation by transforming growth factor-beta","volume":"37","author":"Tannehill-Gregg","year":"2001","journal-title":"Vitro Cellular & Developmental Biology Animal"},{"key":"10.1016\/j.tvjl.2026.106648_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2025.1663990","article-title":"Feline oral squamous cell carcinoma: recent advances and future perspectives","volume":"12","author":"Tutu","year":"2025","journal-title":"Frontiers in Veterinary Science"},{"key":"10.1016\/j.tvjl.2026.106648_bib32","article-title":"Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine","volume":"15","author":"Wang","year":"2025","journal-title":"Animals an Open Access Journal from MDPI"},{"key":"10.1016\/j.tvjl.2026.106648_bib33","article-title":"Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role","volume":"8","author":"Wang","year":"2020","journal-title":"Frontiers in Cell and developmental Biology"},{"key":"10.1016\/j.tvjl.2026.106648_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1759-7714.12325","article-title":"MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation","volume":"7","author":"Wang","year":"2016","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.tvjl.2026.106648_bib35","article-title":"Direct antitumor activity of bevacizumab: an overlooked mechanism?","volume":"15","author":"Wang","year":"2024","journal-title":"Frontiers in pharmacology"},{"key":"10.1016\/j.tvjl.2026.106648_bib36","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.7314\/APJCP.2015.16.15.6501","article-title":"Bevacizumab Regulates Cancer Cell Migration by Activation of STAT3","volume":"16","author":"Wu","year":"2015","journal-title":"Asian Pacific journal of cancer prevention APJCP"},{"key":"10.1016\/j.tvjl.2026.106648_bib37","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1167\/iovs.07-1175","article-title":"Interaction between bevacizumab and murine VEGF-A: a reassessment","volume":"49","author":"Yu","year":"2008","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.tvjl.2026.106648_bib38","doi-asserted-by":"crossref","first-page":"9697","DOI":"10.1002\/cam4.5674","article-title":"Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study","volume":"12","author":"Zhai","year":"2023","journal-title":"Cancer Medicine"}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023326001048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023326001048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:14:10Z","timestamp":1780017250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090023326001048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"alternative-id":["S1090023326001048"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2026.106648","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of VEGF-A\/VEGFR-2 pathway in feline oral squamous cell carcinoma in vitro and anti-tumour effect of Bevacizumab in a xenograft model","name":"articletitle","label":"Article Title"},{"value":"The Veterinary Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvjl.2026.106648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106648"}}